PubRank

Robert L Sutherland

Author PubWeight™ 199.81‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 International network of cancer genome projects. Nature 2010 20.35
2 Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012 8.31
3 Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009 5.89
4 Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011 5.76
5 Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A 2010 2.67
6 International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2002 2.51
7 Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003 2.31
8 Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One 2007 2.26
9 Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol 2013 2.26
10 Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 2009 2.21
11 Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003 2.14
12 Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009 1.98
13 A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003 1.96
14 The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007 1.95
15 Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009 1.94
16 Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell 2012 1.91
17 PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010 1.89
18 Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003 1.81
19 DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002 1.78
20 Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 2005 1.73
21 Cell cycle control in breast cancer cells. J Cell Biochem 2006 1.68
22 Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 2004 1.65
23 Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res 2010 1.62
24 Outcomes of transperineal template-guided prostate biopsy in 409 patients. BJU Int 2013 1.55
25 EphB4 expression and biological significance in prostate cancer. Cancer Res 2005 1.53
26 Molecular markers of prostate cancer outcome. Eur J Cancer 2005 1.52
27 An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005 1.52
28 Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res 2005 1.48
29 Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer 2003 1.47
30 Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 2003 1.43
31 Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One 2008 1.42
32 Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. Proc Natl Acad Sci U S A 2005 1.41
33 The E3 ubiquitin ligase EDD regulates S-phase and G(2)/M DNA damage checkpoints. Cell Cycle 2007 1.36
34 EDD, the human hyperplastic discs protein, has a role in progesterone receptor coactivation and potential involvement in DNA damage response. J Biol Chem 2002 1.34
35 Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol 2009 1.32
36 The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res 2005 1.32
37 Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev 2010 1.31
38 Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res 2008 1.30
39 Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol 2002 1.28
40 Edd, the murine hyperplastic disc gene, is essential for yolk sac vascularization and chorioallantoic fusion. Mol Cell Biol 2004 1.28
41 Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol 2008 1.28
42 Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 2009 1.27
43 The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. Oncogene 2002 1.26
44 Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS One 2009 1.25
45 Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res 2011 1.25
46 EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene 2003 1.23
47 c-Myc overexpression and endocrine resistance in breast cancer. J Steroid Biochem Mol Biol 2006 1.22
48 Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res 2002 1.21
49 EDD mediates DNA damage-induced activation of CHK2. J Biol Chem 2006 1.21
50 Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 2004 1.21
51 Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1. Oncogene 2005 1.20
52 Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res 2011 1.18
53 Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res 2009 1.17
54 Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol 2011 1.17
55 ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLoS Biol 2012 1.16
56 Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res 2009 1.16
57 Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc. Mol Cell Biol 2009 1.16
58 Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Res 2011 1.14
59 Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 2007 1.14
60 Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2004 1.13
61 Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 2004 1.13
62 Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer 2005 1.12
63 Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol 2004 1.11
64 Cell cycle proteins in epithelial cell differentiation: implications for breast cancer. Cell Cycle 2010 1.10
65 Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1. Cell Cycle 2013 1.09
66 β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. Cancer Res 2013 1.08
67 Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiol Biomarkers Prev 2006 1.07
68 Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. Cancer Epidemiol Biomarkers Prev 2010 1.07
69 Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. PLoS One 2011 1.07
70 Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 2002 1.07
71 Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer 2011 1.07
72 Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 2003 1.06
73 Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate 2004 1.06
74 Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate 2008 1.05
75 Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev 2010 1.05
76 The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. Cancer Epidemiol Biomarkers Prev 2005 1.04
77 Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells. Cell Cycle 2013 1.03
78 Lymphatic vessel density and lymph node metastasis in prostate cancer. Prostate 2005 1.03
79 Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006 1.03
80 Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers. Cancer Lett 2011 1.02
81 Regulation of the ubiquitin-conjugating enzyme hHR6A by CDK-mediated phosphorylation. EMBO J 2002 1.02
82 Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer 2014 1.01
83 Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther 2004 1.01
84 Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther 2012 1.01
85 Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development. Int J Cancer 2010 1.01
86 Transcription factor ATF3 links host adaptive response to breast cancer metastasis. J Clin Invest 2013 1.00
87 Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics. Crit Rev Oncog 2012 1.00
88 Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Res 2012 0.98
89 p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Res 2003 0.98
90 Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer. Prostate 2007 0.98
91 HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. Mol Cell Endocrinol 2008 0.98
92 Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer 2003 0.97
93 Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers. Cancer Epidemiol Biomarkers Prev 2010 0.97
94 Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol Biomarkers Prev 2006 0.97
95 Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum Genet 2011 0.96
96 Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro. Clin Cancer Res 2004 0.96
97 E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res 2003 0.95
98 The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini. Cancer Res 2008 0.93
99 TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers. Mol Cell Biol 2012 0.93
100 Live or let die: oestrogen regulation of survival signalling in endocrine response. Breast Cancer Res 2007 0.92
101 CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res 2009 0.92
102 High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology 2010 0.92
103 Methylation-capture and Next-Generation Sequencing of free circulating DNA from human plasma. BMC Genomics 2014 0.91
104 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Cancer 2007 0.91
105 The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. Breast Cancer Res 2011 0.91
106 Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. FEBS J 2013 0.91
107 Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int J Cancer 2003 0.91
108 Pancreatic intraepithelial neoplasia in association with intraductal papillary mucinous neoplasms of the pancreas: implications for disease progression and recurrence. Am J Surg Pathol 2004 0.90
109 Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. PLoS One 2012 0.89
110 Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1. Eur J Nutr 2006 0.89
111 Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor. Cancer Res 2007 0.89
112 Overexpression of E2F-1 is associated with increased disease-free survival in squamous cell carcinoma of the anterior tongue. Clin Cancer Res 2003 0.88
113 Genetic variants in the vitamin D receptor gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005 0.88
114 Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. Histopathology 2009 0.86
115 TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma. Cancer Epidemiol Biomarkers Prev 2011 0.86
116 Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions. Cancer 2008 0.86
117 High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU Int 2011 0.86
118 Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival. Cancer Epidemiol Biomarkers Prev 2006 0.85
119 The cyclin-dependent kinase inhibitor p27 (Kip1) regulates both DNA synthesis and apoptosis in mammary epithelium but is not required for its functional development during pregnancy. Mol Endocrinol 2003 0.85
120 MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer 2010 0.85
121 Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer. Prostate 2011 0.84
122 The Hedgehog signalling pathway as a therapeutic target in early breast cancer development. Expert Opin Ther Targets 2009 0.84
123 Messina: a novel analysis tool to identify biologically relevant molecules in disease. PLoS One 2009 0.84
124 RON is not a prognostic marker for resectable pancreatic cancer. BMC Cancer 2012 0.83
125 Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism. Mol Cancer Ther 2007 0.83
126 Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy. J Urol 2010 0.83
127 Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiol Biomarkers Prev 2008 0.82
128 The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome. Breast Cancer Res 2008 0.82
129 RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease. Cell Cycle 2010 0.82
130 Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4. Breast Cancer Res 2011 0.82
131 Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways. J Bone Miner Res 2014 0.82
132 Synthesis and in vitro evaluation of analogues of avocado-produced toxin (+)-(R)-persin in human breast cancer cells. Bioorg Med Chem 2011 0.82
133 LMO4 expression in squamous cell carcinoma of the anterior tongue. Histopathology 2011 0.81
134 Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. Int J Cancer 2010 0.81
135 Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells. Endocrinology 2003 0.81
136 p14ARF protein expression is a predictor of both relapse and survival in squamous cell carcinoma of the anterior tongue. Clin Cancer Res 2005 0.81
137 A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cells. Mol Cancer Ther 2006 0.80
138 Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. J Clin Pathol 2006 0.80
139 Cyclin E expression and outcome in pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006 0.80
140 The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. BJU Int 2007 0.80
141 Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. J Bone Miner Res 2002 0.79
142 Retinoid signaling in pancreatic cancer, injury and regeneration. PLoS One 2011 0.79
143 Identification of downstream targets of estrogen and c-myc in breast cancer cells. Adv Exp Med Biol 2008 0.79
144 ZNF300P1 encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer. Mol Cancer 2014 0.79
145 High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse. BJU Int 2012 0.77
146 Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram. BJU Int 2009 0.75